Connection

Yuko Palesch to Tissue Plasminogen Activator

Back to Details
This is a "connection" page, showing publications Yuko Palesch has written about Tissue Plasminogen Activator.
Yuko Palesch
Connection Strength
2.575
Tissue Plasminogen Activator
  1. Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. PLoS One. 2017; 12(10):e0187050.
    View in: PubMed
    Score: 0.486
  2. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013 06 20; 368(25):2432-3.
    View in: PubMed
    Score: 0.359
  3. Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc. 2017 May 08; 6(5).
    View in: PubMed
    Score: 0.118
  4. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016 Feb; 47(2):581-641.
    View in: PubMed
    Score: 0.107
  5. Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1321-7.
    View in: PubMed
    Score: 0.102
  6. A surrogate-primary replacement algorithm for response-adaptive randomization in stroke clinical trials. Stat Methods Med Res. 2017 Jun; 26(3):1078-1092.
    View in: PubMed
    Score: 0.100
  7. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis. Stroke. 2015 Feb; 46(2):461-4.
    View in: PubMed
    Score: 0.100
  8. Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions. J Neurointerv Surg. 2015 Nov; 7(11):795-802.
    View in: PubMed
    Score: 0.099
  9. Evolution of practice during the Interventional Management of Stroke III Trial and implications for ongoing trials. Stroke. 2014 Dec; 45(12):3606-11.
    View in: PubMed
    Score: 0.098
  10. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. Radiology. 2014 Oct; 273(1):202-10.
    View in: PubMed
    Score: 0.096
  11. Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial. Stroke. 2014 Jun; 45(6):1791-8.
    View in: PubMed
    Score: 0.096
  12. Regression analysis of ordinal stroke clinical trial outcomes: an application to the NINDS t-PA trial. Int J Stroke. 2014 Feb; 9(2):226-31.
    View in: PubMed
    Score: 0.090
  13. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 07; 368(10):893-903.
    View in: PubMed
    Score: 0.088
  14. Covariate imbalance and adjustment for logistic regression analysis of clinical trial data. J Biopharm Stat. 2013; 23(6):1383-402.
    View in: PubMed
    Score: 0.087
  15. Measuring continuous baseline covariate imbalances in clinical trial data. Stat Methods Med Res. 2015 Apr; 24(2):255-72.
    View in: PubMed
    Score: 0.079
  16. Quantifying the cost in power of ignoring continuous covariate imbalances in clinical trial randomization. Contemp Clin Trials. 2011 Mar; 32(2):250-9.
    View in: PubMed
    Score: 0.075
  17. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke. 2010 Nov; 41(11):2581-6.
    View in: PubMed
    Score: 0.074
  18. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke. 2008 May; 3(2):130-7.
    View in: PubMed
    Score: 0.063
  19. Using the baseline CT scan to select acute stroke patients for IV-IA therapy. AJNR Am J Neuroradiol. 2006 Sep; 27(8):1612-6.
    View in: PubMed
    Score: 0.056
  20. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis. Stroke. 2006 Aug; 37(8):2107-14.
    View in: PubMed
    Score: 0.055
  21. Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke: Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data. Stroke. 2015 Dec; 46(12):3416-22.
    View in: PubMed
    Score: 0.026
  22. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):567-74.
    View in: PubMed
    Score: 0.024
  23. Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke. 2014 May; 45(5):1408-14.
    View in: PubMed
    Score: 0.024
  24. Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial. Stroke. 2014 Mar; 45(3):759-64.
    View in: PubMed
    Score: 0.023
  25. Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial. Stroke. 2014 Feb; 45(2):444-9.
    View in: PubMed
    Score: 0.023
  26. The albumin in acute stroke trial (ALIAS); design and methodology. Int J Stroke. 2007 Aug; 2(3):214-9.
    View in: PubMed
    Score: 0.015
  27. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results. Stroke. 2006 Aug; 37(8):2100-6.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.